Skip to main content

Homepage

Videos

Videos
Rakesh Jain, MD and Brooke Kempf, PMHNP-BC discuss the latest issues around partial response and treatment resistance in major depressive disorder.
Videos
Join Dr. Rakesh Jain as he reviews the mechanism of action of brexpiprazole.
Videos
Meet the experts for this debate on the complex relationship between MDD and PPD. Jennifer Payne, MD, asserts that PPD is one type of MDD that is likely to be more homogenous from a biological and environmental perspective than other types. Melanie Barrett, MD, points to the evidence that many women who develop PPD have had a history of MDD and will go on to have additional episodes of MDD outside of the peripartum period.
Videos
Dr. Charles DeBattista discusses the ongoing unmet needs in the treatment of major depressive disorder (MDD).

News

News

Rakesh Jain, MD, and Greg Mattingly, MD, answered audience questions regarding the potential of GABA and glutamate modulation in understanding and treating the psychological impact of traumatic brain injury (TBI) in the frontal lobe, as well as positive insights on the newer depression treatment options available and the flexibility of those approac

News

Antidepressant prescribing patterns and outcomes for patients with major depressive disorder (MDD) vary significantly between prescriber groups, suggest study findings published in JAMA Psychiatry.

News

Individuals with major depressive disorder (MDD) may have significant moderate cognitive deficits in executive function, memory, and attention, but not in reaction time, when compared to healthy subjects. Researchers published their findings from a recent comprehensive review and meta-analysis in Psychotherapy and Psychosomatics. 

News

Multilocus sequential repetitive transcranial magnetic stimulation (rTMS) reduced tinnitus symptom severity in both patients with and without comorbid major depressive disorder (MDD) in a recent open-label treatment study published in Neuromodulation.

News

The US Food and Drug Administration (FDA) approved Rejoyn, the first prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms.

Education

Education

Clinical Considerations and Strategies in BD vs MDD

Education

An Invisible Enemy in MDD, Neurobiology and Emerging Precision Treatments

Education
Reducing Residual Symptoms and Side Effects Through the Use of Precision Serotonin Receptor Modulation

Posters

Posters

RELIEVE was a 24-week, observational, prospective, international cohort study in outpatients with MDD initiating vortioxetine treatment at their physician’s discretion in routine care settings (NCT03555136).

Posters

The relationship between anhedonia severity and the clinical and humanistic burden among patients with MDD is poorly understood. 

Posters

This retrospective cohort study used an insurer’s claims database. Patients (≥18 years) were included based on newly diagnosed MDD (ICD-10) recorded by a PCP or a Psychiatric provider (PSY) from 1/1/2019 to 12/31/2021, and followed for 12 months.